Enveric Biosciences Expands At-The-Market Equity Offering Capacity

An announcement from Enveric Biosciences ( (ENVB) ) is now available.

On February 6, 2026, Enveric Biosciences, Inc. filed a prospectus supplement to register an additional $1,346,000 of common stock under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC, expanding its capacity to raise capital through incremental share sales. The company has previously sold approximately $1.85 million of common stock under this program, and the new registration, supported by a legal opinion on the validity of the shares, underscores its continued reliance on at-the-market equity issuance as a funding mechanism, with implications for its capital structure and existing shareholders’ dilution.

The most recent analyst rating on (ENVB) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.

Spark’s Take on ENVB Stock

According to Spark, TipRanks’ AI Analyst, ENVB is a Neutral.

The score is held down primarily by weak financial performance (no revenue, continued losses and cash burn) and bearish technicals (price far below key moving averages with negative MACD). Corporate events provide some offset via fresh funding and regained Nasdaq compliance, but valuation support is limited due to negative earnings and no dividend.

To see Spark’s full report on ENVB stock, click here.

More about Enveric Biosciences

Enveric Biosciences, Inc. operates in the biopharmaceutical sector and is listed as an issuer of common stock, suggesting a focus on developing and funding life sciences or healthcare-related products through public equity markets.

Average Trading Volume: 708,687

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.95M

Find detailed analytics on ENVB stock on TipRanks’ Stock Analysis page.